Introgen’s Advexin Doubles Survival In Some Head & Neck Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm plans end-of-June filing in U.S. and EU for p53 tumor suppressor in recurrent head and neck cancer.
You may also be interested in...
Introgen Files Advexin For Head And Neck Cancer In U.S., EU
Biotech says it hopes to follow the Idec/Rituxan model in bringing oncologic gene therapy to the U.S. market.
Introgen Files Advexin For Head And Neck Cancer In U.S., EU
Biotech says it hopes to follow the Idec/Rituxan model in bringing oncologic gene therapy to the U.S. market.
Introgen Advexin Data Strengthens Biomarker Case In Head And Neck Cancer Patients
BLA filing for the p53 tumor suppressor remains on track for the second quarter, Medical and Scientific Affairs VP Sobol tells “The Pink Sheet” DAILY.